Currently, mutational profiles are applied for selection of targeted therapeutics for e.g. BRAF inhibitors in malignant melanoma [17] and BRAF and EGFR targeting in lung- and colorectal cancers [18], [19]. This evidence concerns the gene BRAF and colorectal cancer.